ORPN - Bio Blast Pharma Stock Price, News & Analysis

$2.16 -0.14 (-6.09 %)
(As of 11/24/2017 04:22 AM ET)
Previous Close$2.30
Today's Range$2.15 - $2.43
52-Week Range$1.49 - $8.55
Volume31,000 shs
Average Volume57,871 shs
Market Capitalization$7.22 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.01

About Bio Blast Pharma (NASDAQ:ORPN)

Bio Blast Pharma logoBioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease. It also focuses on diseases with severe and debilitating manifestations. The Company has several drug candidates in clinical or preclinical development targeting neuromuscular/central nervous system (CNS) and mitochondrial diseases. Its drug candidates include Trehalose IV Solution, BB-FA (Bioblast-Friedreich's ataxia) and BBrm-02. The Company's product candidate platforms include Protein Stabilizing Platform, Read-through Platform and Mitochondrial Protein Replacement Platform.


Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ORPN
CUSIPN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio8.08%
Quick Ratio8.08%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.12 per share
Price / Book1.93

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($2.57)
Net Income$-16,020,000.00
Net MarginsN/A
Return on Equity-144.37%
Return on Assets-119.42%

Miscellaneous

Employees12
Outstanding Shares3,340,000

Frequently Asked Questions for Bio Blast Pharma (NASDAQ:ORPN)

What is Bio Blast Pharma's stock symbol?

Bio Blast Pharma trades on the NASDAQ under the ticker symbol "ORPN."

When did Bio Blast Pharma's stock split? How did Bio Blast Pharma's stock split work?

Bio Blast Pharma shares reverse split on the morning of Monday, September 25th 2017. The 1-5 reverse split was announced on Monday, September 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 22nd 2017. An investor that had 100 shares of Bio Blast Pharma stock prior to the reverse split would have 20 shares after the split.

How were Bio Blast Pharma's earnings last quarter?

Bio Blast Pharma Ltd. (NASDAQ:ORPN) announced its quarterly earnings results on Thursday, August, 25th. The biopharmaceutical company reported ($1.10) EPS for the quarter, topping the Zacks' consensus estimate of ($1.35) by $0.25. During the same period in the previous year, the company posted ($1.30) earnings per share. View Bio Blast Pharma's Earnings History.

When will Bio Blast Pharma make its next earnings announcement?

Bio Blast Pharma is scheduled to release their next quarterly earnings announcement on Friday, February, 23rd 2018. View Earnings Estimates for Bio Blast Pharma.

Where is Bio Blast Pharma's stock going? Where will Bio Blast Pharma's stock price be in 2017?

0 brokerages have issued 12-month price targets for Bio Blast Pharma's stock. Their predictions range from $3.15 to $3.15. On average, they anticipate Bio Blast Pharma's share price to reach $3.15 in the next twelve months. View Analyst Ratings for Bio Blast Pharma.

Who are some of Bio Blast Pharma's key competitors?

How do I buy Bio Blast Pharma stock?

Shares of Bio Blast Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bio Blast Pharma's stock price today?

One share of Bio Blast Pharma stock can currently be purchased for approximately $2.16.

How big of a company is Bio Blast Pharma?

Bio Blast Pharma has a market capitalization of $7.22 million. The biopharmaceutical company earns $-16,020,000.00 in net income (profit) each year or ($2.57) on an earnings per share basis. Bio Blast Pharma employs 12 workers across the globe.

How can I contact Bio Blast Pharma?

Bio Blast Pharma's mailing address is 37 Dereh Menechem Begin St. 15th Floor, Tel Aviv L3, 6522042. The biopharmaceutical company can be reached via phone at 972-72-240-9060 or via email at [email protected]


MarketBeat Community Rating for Bio Blast Pharma (ORPN)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  125 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  190
MarketBeat's community ratings are surveys of what our community members think about Bio Blast Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Bio Blast Pharma (NASDAQ:ORPN)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: $3.15 (45.83% upside)

Consensus Price Target History for Bio Blast Pharma (NASDAQ:ORPN)

Price Target History for Bio Blast Pharma (NASDAQ:ORPN)

Analysts' Ratings History for Bio Blast Pharma (NASDAQ:ORPN)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/28/2017S&P Equity ResearchBoost Price Target$2.80 -> $3.15LowView Rating Details
10/24/2016Roth CapitalSet Price TargetBuy$75.00N/AView Rating Details
7/11/2016Rodman & RenshawReiterated RatingBuyN/AView Rating Details
1/28/2016HC WainwrightInitiated CoverageBuy$125.00N/AView Rating Details
11/27/2015Oppenheimer Holdings, Inc.Reiterated RatingOutperform$160.00N/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for Bio Blast Pharma (NASDAQ:ORPN)

Earnings by Quarter for Bio Blast Pharma (NASDAQ:ORPN)

Earnings History by Quarter for Bio Blast Pharma (NASDAQ ORPN)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2018        
8/25/2016Q2($1.35)($1.10)ViewN/AView Earnings Details
5/25/2016Q1($1.45)($1.60)ViewN/AView Earnings Details
2/23/2016Q4($1.25)($1.70)ViewN/AView Earnings Details
11/17/2015Q3($1.45)($1.25)ViewN/AView Earnings Details
8/21/2015Q2($1.40)($1.30)ViewN/AView Earnings Details
5/19/2015Q115($1.25)($1.15)ViewN/AView Earnings Details
2/17/2015Q414($0.80)($1.10)ViewN/AView Earnings Details
11/21/2014($0.45)($0.80)ViewN/AView Earnings Details
8/29/2014Q214($0.45)($0.50)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bio Blast Pharma (NASDAQ:ORPN)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Bio Blast Pharma (NASDAQ:ORPN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Bio Blast Pharma (NASDAQ ORPN)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Bio Blast Pharma (NASDAQ ORPN)

Source:
DateHeadline
Bioblast Pharma Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)Bioblast Pharma Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 4 at 8:36 AM
Bioblast Pharma Reports Third Quarter 2017 Financial ResultsBioblast Pharma Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 4 at 8:36 AM
Bio Blast reports 3Q lossBio Blast reports 3Q loss
finance.yahoo.com - November 4 at 8:36 AM
Should You Invest In The Healthcare Stock Bioblast Pharma Ltd (ORPN)?Should You Invest In The Healthcare Stock Bioblast Pharma Ltd (ORPN)?
finance.yahoo.com - November 4 at 8:36 AM
Bioblast Announces Effectiveness of Five to One Reverse SplitBioblast Announces Effectiveness of Five to One Reverse Split
finance.yahoo.com - October 2 at 9:20 PM
Head to Head Review: Bio Blast Pharma (ORPN) versus Its PeersHead to Head Review: Bio Blast Pharma (ORPN) versus Its Peers
www.americanbankingnews.com - September 30 at 6:26 AM
Bioblast Pharma Reports Second Quarter 2017 Financial ResultsBioblast Pharma Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 5 at 5:38 AM
Bio Blast reports 2Q lossBio Blast reports 2Q loss
finance.yahoo.com - August 5 at 5:38 AM
BioBlast Pharma (ORPN) to Seek Strategic Alternatives Including Partnership or Merger - StreetInsider.comBioBlast Pharma (ORPN) to Seek Strategic Alternatives Including Partnership or Merger - StreetInsider.com
www.streetinsider.com - June 6 at 8:24 AM
Bioblast Pharma Reports First Quarter 2017 Financial Results - GlobeNewswire (press release)Bioblast Pharma Reports First Quarter 2017 Financial Results - GlobeNewswire (press release)
www.globenewswire.com - May 28 at 5:26 AM
Bioblast Pharma Reports First Quarter 2017 Financial Results - NasdaqBioblast Pharma Reports First Quarter 2017 Financial Results - Nasdaq
www.nasdaq.com - May 26 at 8:14 PM
Bioblast Pharma Announces Plans in Response to Nasdaq Notifications Regarding Stockholders Equity and Minimum ... - NasdaqBioblast Pharma Announces Plans in Response to Nasdaq Notifications Regarding Stockholders' Equity and Minimum ... - Nasdaq
www.nasdaq.com - April 20 at 12:08 AM
Bioblast Pharma Announces Receipt of Nasdaq Notification Regarding Stockholders’ EquityBioblast Pharma Announces Receipt of Nasdaq Notification Regarding Stockholders’ Equity
us.rd.yahoo.com - March 10 at 8:52 PM
Bioblast Pharma Reports Fourth Quarter and Year End 2016 Financial ResultsBioblast Pharma Reports Fourth Quarter and Year End 2016 Financial Results
us.rd.yahoo.com - February 24 at 8:45 AM
Bioblast Pharma Provides Clinical and Development Updates on Trehalose as a Potential Therapeutic for OPMD and Other Neurodegenerative DiseasesBioblast Pharma Provides Clinical and Development Updates on Trehalose as a Potential Therapeutic for OPMD and Other Neurodegenerative Diseases
us.rd.yahoo.com - February 2 at 7:59 PM
4:02 pm Bio Blast Pharma announces clinical update related to its proprietary intravenous (:IV) form of trehalose 90 mg/mL solution, which is being evaluated as a potential therapeutic, initially for oculopharyngeal muscular dystrophy4:02 pm Bio Blast Pharma announces clinical update related to its proprietary intravenous (:IV) form of trehalose 90 mg/mL solution, which is being evaluated as a potential therapeutic, initially for oculopharyngeal muscular dystrophy
us.rd.yahoo.com - February 2 at 7:59 PM

Social Media

Financials

Chart

Bio Blast Pharma (NASDAQ ORPN) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.